Drugs / Acoradine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT06644937 | Nov 2024 → Oct 2026 expected | hepatocellular carcinoma | Zhujiang Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Acoradine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06644937 ↗ |
| Route | Oral | “6 tablets bid, taken after meals” NCT06644937 ↗ |